MedTrace Logo

Dexmedetomidine as an Additive for (Ipack)Block in Knee Surgery

NCT07058493 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-07-10

No results posted yet for this study

Summary

Dexmedetomidine used as an Additive for Ipack Block in Knee Surgery

Conditions

  • Knee Surgeries

Interventions

DRUG

Dexmedetomidine

dexmedetomidine 100 μg as adjuvant to IPACK block with 20 ml of bupivacaine 0.25%.

DRUG

Bupivacaine

20 ml of bupivacaine 0.25%.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Dalia K Ismail · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2024-07-10
Completion
2024-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07058493 on ClinicalTrials.gov